Ceftibuten (7432-S, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines
- 56 Downloads
The antimicrobial activity of ceftibuten, a new oral cephalosporin, was evaluated using 4735 clinical bacterial isolates processed at four medical centers. Ceftibuten inhibited nearly 92 % of allEnterobacteriaceae (⩽ 8.0µg/ml), thereby being markedly superior to cefixime which inhibited 78.7 % at ⩽1.0µg/ml and cefuroxime which inhibited 45.1 % at ⩽2.0µg/ml. Pseudomonads and staphylococci were not within the spectrum of activity of ceftibuten. Ceftibuten was found to be very stable in the presence of five commonly occurring beta-lactamases of both the chromosomal-mediated (P99, K1) and plasmid-mediated (CARB-2, OXA-1, TEM-1) types. Only Type Ia (P99) beta-lactamase was significantly inhibited by ceftibuten. On the basis of results of a ceftibuten MIC quality control study conducted in five laboratories, a quality control range of 0.12 to 0.5µg/ml is recommended for theEscherichia coli ATCC 25922 strain.
KeywordsInternal Medicine Quality Control Antimicrobial Activity Cephalosporin Medical Center
Unable to display preview. Download preview PDF.
- 1.Barry, A. L., Thornsberry, C., Jones, R. N. Cefuroxime, in vitro comparison to six other cephalosporins. Proceedings of the Royal Society of Medicine 1977, 70, Supplement 9: 63–71.Google Scholar
- 3.Fuchs, P. C., Jones, R. N., Barry, A. L., Thornsberry, C., Ayers, L. W., Gavan, T. L., Gerlach, E. H. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Diagnostic Microbiology and Infectious Disease 1986, 5: 151–162.CrossRefGoogle Scholar
- 4.Guay, D. R. P., Meatherall, R. C., Harding, G. K., Brown, G. R. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrobial Agents and Chemotherapy 1986, 30: 483–490.Google Scholar
- 8.Preston, D. A., Jones, R. N., Barry, A. L., Thornsberry, C. Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: re-evaluation of the class representative concept of susceptibility testing. Journal of Clinical Microbiology 1983, 17: 1156–1158.PubMedGoogle Scholar
- 9.National Committee for Clinical Laboratory Standards: Approved standard M7-A. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova, PA, 1985.Google Scholar
- 10.Barry, A. L., Gavan, T. L., Jones, R. N., Ayers, L. W., Fuchs, P. C., Gerlach, E. H., Thornsberry, C. Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime and cefonicid. Diagnostic Microbiology and Infectious Disease 1987, 7: 83–87.CrossRefPubMedGoogle Scholar
- 11.National Committee for Clinical Laboratory Standards: Proposed guideline, M23-P. Development of in vitro susceptibility testing criteria and quality control parameters. Villanova, PA, 1987.Google Scholar
- 15.Shimada, J., Saito, A., Shimada, K. T-2588, a third-generation oral cephalosporin: human pharmacokinetics. In: Ishigami, J. (ed.): Recent advances in chemotherapy. University of Tokyo Press, Tokyo, 1986.Google Scholar